Cogstate Limited revised earnings guidance for the fiscal year ending 30 June 2023. For the year, revenue expected to be approximately 6% to 9% below fiscal year 2022; EBIT is expected to be in the range of 6% to 8% of revenue (4 November 2022 guidance of 20% to 24%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.29 AUD | +3.20% | +0.78% | -10.73% |
Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
Feb. 22 | Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.73% | 143M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- CGS Stock
- News Cogstate Limited
- Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023